Novartis India announces results for the quarter and year ended March 31, 2017

May 24, 2017

- Full year profits from continuing operations severly impacted by price controls
- Board recommends dividend of ₹10 per equity share of ₹ each

At a meeting held in Mumbai today, the Board of Novartis India Limited approved results for the quarter and financial year ended March 31, 2017 and recommended dividend of ₹10 per equity share of ₹5 each.

During the quarter under review, Total Income was ₹160.3 crore in comparison to ₹187.2 crore recorded in the previous corresponding quarter.

Total Comprehensive Income for the quarter under review was ₹4.9 crore as against ₹21.6 crore in the previous corresponding quarter.

During FY 2016-2017 Total Income stood at ₹726.4 crore in comparison to ₹770.8 crore recorded in the previous corresponding period.

During the year ended under review, profit before tax from continuing operations was ₹ 91.7 crore as against profit of ₹ 111.4 crore in the previous corresponding period. Profit was impacted as the Company has had a substantial impact on account of reduction in prices of products covered under NLEM.

Total Comprehensive Income for FY 2016-2017 was ₹ 57.7 crore as against ₹ 198.6 crore in the previous corresponding full year period. Previous corresponding period FY 2015-2016 includes Profit of ₹ 125.8 crore from discontinued operations of OTC division and Animal Health division.

Issued by Corporate Communications on May 23, 2017

Media contacts

Liana Albuquerque

+91 22 24939403 (direct)

+91 98214 36458 (mobile)

liana.albuquerque@novartis.com

Source URL: https://www.novartis.com/in-en/news/media-releases/novartis-india-announces-results-quarter-and-year-ended-march-31-2017

List of links present in page

- https://www.novartis.com/in-en/in-en/news/media-releases/novartis-india-announces-results-quarter-and-year-ended-march-31-2017
- mailto:liana.albuquerque@novartis.com